Status:
COMPLETED
Study Of Axitinib In Combination With Cisplatin And Capecitabine In Patients With Advanced Gastric Cancer
Lead Sponsor:
Pfizer
Conditions:
Stomach Neoplasms
Advanced Gastric Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine the safe and tolerable dose of axitinib given together with cisplatin and capecitabine in patients with advanced gastric cancer who have not received prior ch...
Eligibility Criteria
Inclusion
- confirmed diagnosis of stomach cancer
- advanced stomach cancer of stage IV
- adequate blood chemistry, blood counts and kidney function
- willing to participate to study requirements and sign an informed consent document
Exclusion
- prior chemotherapy for stomach cancer in its advanced stage
- excessive toxicities related to prior therapies
- pregnant or breastfeeding patients
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2012
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT00842244
Start Date
April 1 2009
End Date
October 1 2012
Last Update
November 27 2013
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Kashiwa, Chiba, Japan
2
Pfizer Investigational Site
Yufu, Oita Prefecture, Japan
3
Pfizer Investigational Site
Goyang-si, Gyeonggi-do, South Korea, 410-769
4
Pfizer Investigational Site
Seongnam-si, Gyeonggi-do, South Korea, 463-707